Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.

Abstract

PURPOSE:

We determined the clinical efficacy and safety of terazosin in the treatment of patients with female lower urinary tract symptoms.

MATERIALS AND METHODS:

A total of 100 females 20 to 70 years old who met the inclusion criteria of total International Prostate Symptom Score 8 or greater, symptom duration 1 or more months, and did not meet any exclusion criteria were entered into the study. Subjects were randomized to receive terazosin or placebo in titrated dose from 1 mg od, 1 mg twice daily to 2 mg twice daily during 14 weeks. Successful treatment outcomes use primary end point of International Prostate Symptom Score quality of life 2 or less and secondary end point of total International Prostate Symptom Score 7 or less. Other outcome measures included International Prostate Symptom Score individual item scores, King's Health Questionnaire quality of life domains, objective assessment parameters of 24-hour frequency volume chart, maximum flow rate and post-void residual urine.

RESULTS:

Using a primary end point, 32 of 40 (80%) evaluable terazosin subjects responded in contrast to 22 of 40 (55%) evaluable placebo subjects (p <0.02). The secondary end point revealed a successful outcome in 85% of terazosin subjects vs 55% in placebo (p <0.01). Of the 7 International Prostate Symptom Score individual item scores, only item scores of frequency and straining showed statistically significant reductions with terazosin (p <0.01). All King's Health Questionnaire quality of life domains except domain of severity measures showed statistically significant improvement with terazosin (p <0.05). There were no differences between treatment groups in all objective assessment parameters. Of all evaluable subjects 23 of 40 (58%) on placebo experienced adverse events vs 16 of 40 (40%) on terazosin (p >0.05).

CONCLUSIONS:

Terazosin proved to be more effective and safe than placebo in patients with female lower urinary tract symptoms.

• Authors: Bee Yean Low, Men Long Liong, Kah Hay Yuen, Christopher Chee, Wing Seng Leong, Wooi Loong Chong, Nurzalina Abdul Karim Khan, Phaik Yeong Cheah, Ker Keong Liong
• Journal: The Journal of urology (J Urol) Vol. 179 Issue 4 Pg. 1461-9 (Apr 2008) ISSN: 1527-3792 [Electronic] United States
• PMID: 18295277 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Adrenergic alpha-Antagonists
• Terazosin
• Prazosin

Topics

• Adrenergic alpha-Antagonists (therapeutic use)
• Adult
• Aged
• Double-Blind Method
• Female
• Humans
• Middle Aged
• Prazosin (analogs & derivatives, therapeutic use)
• Urination Disorders (drug therapy)